OUR SOLUTIONS / VASOSPASM

Take command
in vasospasm

COMANECI™ is the only active assist device with the versatility to treat wide-neck aneurysms and restore arteries in vasospasm, providing results without permanent implants.

OUR SOLUTIONS / VASOSPASM

Take command
in vasospasm

COMANECI™ is the only active assist device with the versatility to treat wide-neck aneurysms and restore arteries in vasospasm, providing results without permanent implants.

Cerebral vasospasm is an orphan disease, and leading cause of death and disability following subarachnoid hemorrhage (SAH),1,2 yet lacks a defined treatment strategy.


COMANECI is the first device to receive FDA breakthrough designation to provide options for these patients.

Cerebral vasospasm is an orphan disease, and leading cause of death and disability following subarachnoid hemorrhage (SAH),1,2 yet lacks a defined treatment strategy.


COMANECI is the 1st device to receive FDA breakthrough designation to provide options for these patients.

Restore the

flow with

active control

Unlike other angioplasty devices, COMANECI’s active technology offers precise control over vessel dilation with full visibility, potentially reducing the risk of vessel injury.1

Gradual expansion can achieve similar results as high-impact balloons–with less damage to the vessel.3 

Restore the

flow with

active control

Unlike other angioplasty devices, COMANECI’s active technology offers precise control over vessel dilation with full visibility, potentially reducing the risk of vessel injury.1

Gradual expansion can achieve similar results as high-impact ballons–with less damage to the vessel.3 

Enable

combination

therapy

The patent design of COMANECI allows dual treatment–mechanical dilation plus the concurrent

infusion of vasodilators. Synergistic action may enhance efficacy compared to a single treatment.

Enable

combination

therapy

The patent design of COMANECI allows dual treatment–mechanical dilation plus the concurrent infusion of vasodilators. Synergistic action may enhance efficacy compared to a single treatment.

The proof is in

the patients

In a multicenter study, severe vessel constriction improved significantly, with 52% of patients achieving favorable outcomes at 6 months. 2

Unlock the data

The proof is in

the patients

In a multicenter study, severe vessel constriction improved significantly, with 52% of patients achieving favorable outcomes at 6 months.2

Unlock the data

Click on a tab below to learn more.

Clinical evidence

PRODUCT OVERVIEW

COMANECI™ is designed with active, responsive technology to enable non-occlusive coil embolization procedures.

SPECIFICATIONS


*Not all products are available in all countries.
Place an order Ask a product question Request an IFU

HOW IT WORKS

1 TREAT distal → proximal

2 Gradually EXPAND COMANECI™

3 WAIT for dilation–on average 2.5 minutes (range 30 sec. – 5 min). 5

Place an order Ask a product question Request an IFU
DR. TUFAIL PATANKAR | Romford, UK
Acomm blister aneurysm with severe vasospasm
View the case →
DR. SVETLANA RUDNICKA | Denmark | Presented at the WIFTN Congress
Single-center experience of active multisessional vasospasm treatment
View the case →
Place an order Ask a product question Request an IFU
×
×
×

Rapid announces Japanese approval and exclusive partnership with Kaneka for TIGERTRIEVER™

Continue Reading →

Rapid Medical's TIGERTRIEVER™ Delivers First-Pass Success in Challenging Ischemic Stroke Patients with ICAD

Continue Reading →

New Data Shows Advantages of Rapid Medical’s COMANECI™ Embolization Assist Device

Continue Reading →

Rapid Medical Gains FDA Clearance for the Smallest & Only Adjustable Thrombectomy Device

Continue Reading →

Leave nothing behind with COMANECI™

Questions?

Reach out to learn more about our company and stroke solutions.

1. Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985;16(4):562-572. doi:10.1161/01.str.16.4.562

2. Salem MM, Khalife J, Desai S, et al. COManeci MechANical Dilation for vasospasm (COMMAND): multicenter experience. J Neurointerv Surg. 2023;15(9):864-870. doi:10.1136/jnis-2022-019272

3. Bhogal P, Pederzani G, Grytsan A, et al. The unexplained success of stentplasty vasospasm treatment : Insights using Mechanistic Mathematical Modeling [published correction appears in Clin Neuroradiol. 2019 Dec;29(4):775. doi: 10.1007/s00062-019-00782-4.]. Clin Neuroradiol. 2019;29(4):763-774. doi:10.1007/s00062-019-00776-2

4. Data on file

5. Hensler J, Larsen N, Wodarg F, et al. P099 Multi-center study to assess effectiveness of the comaneci device in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH)- interim results. Journal of NeuroInterventional Surgery 2024;16:A88.